Joan L. Walker — Endo Lab

nonrandomized-trial 2018

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

Gynecologic Oncology ·doi:10.1016/j.ygyno.2018.05.029

OBJECTIVES: To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients. METHODS: All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear …

rct 2016

Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis

Gynecologic Oncology ·doi:10.1016/j.ygyno.2016.10.016

OBJECTIVES: We sought to analyze the clinicopathologic features, recurrence patterns and survival outcomes of women with high-grade uterine cancer (UC) enrolled on The Gynecologic Oncology Group (GOG) LAP2 trial. METHODS: This is a post-ho…

nonrandomized-trial 2014

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199

Journal of Clinical Oncology ·doi:10.1200/jco.2013.54.1987

PURPOSE: Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal and breast cancers among BRCA1/2 mutation carriers. Uncertainties persist regarding potential benefits of RRSO among high-risk noncarriers, optimal surg…

2012

Expression patterns of the Wnt pathway inhibitors Dickkopf3 (Dkk3) and secreted frizzled-related proteins (SFRP) 1 and 4 in endometrial endometrioid adenocarcinoma: A Gynecologic Oncology Group study

·doi:10.1016/j.ygyno.2011.12.346